Papillary thyroid cancer surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
[[Surgery]] is the mainstay of treatment for papillary thyroid cancer. [[Surgical]] [[interventions]] of papillary thyroid cancer include total [[thyroidectomy]] and [[lobectomy]]. Each of these has its [[indications]]. | [[Surgery]] is the mainstay of treatment for papillary thyroid cancer. [[Surgical]] [[interventions]] of papillary thyroid cancer include total [[thyroidectomy]] and [[lobectomy]]. Each of these has its [[Indications and usage|indications]]. | ||
==Surgery== | ==Surgery== | ||
* [[Surgery]] remains the mainstay of treatment for papillary thyroid cancer.<ref name="urlNCCN Clinical Practice Guidelines in Oncology">{{cite web |url=https://www.nccn.org/professionals/physician_gls/default.aspx#site |title=NCCN Clinical Practice Guidelines in Oncology |format= |work= |accessdate=}}</ref><ref name="pmid18953806">{{cite journal |vauthors=Bilimoria KY, Zanocco K, Sturgeon C |title=Impact of surgical treatment on outcomes for papillary thyroid cancer |journal=Adv Surg |volume=42 |issue= |pages=1–12 |date=2008 |pmid=18953806 |doi= |url=}}</ref><ref name="pmid22435914">{{cite journal |vauthors=Stack BC, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, Sosa JA, Tufano RP |title=American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer |journal=Thyroid |volume=22 |issue=5 |pages=501–8 |date=May 2012 |pmid=22435914 |doi=10.1089/thy.2011.0312 |url=}}</ref><ref name="pmid25590215">{{cite journal |vauthors=Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Torregrossa L, Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, Miccoli P |title=Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study |journal=J. Clin. Endocrinol. Metab. |volume=100 |issue=4 |pages=1316–24 |date=April 2015 |pmid=25590215 |doi=10.1210/jc.2014-3825 |url=}}</ref> | * [[Surgery]] remains the mainstay of treatment for papillary thyroid cancer.<ref name="urlNCCN Clinical Practice Guidelines in Oncology">{{cite web |url=https://www.nccn.org/professionals/physician_gls/default.aspx#site |title=NCCN Clinical Practice Guidelines in Oncology |format= |work= |accessdate=}}</ref><ref name="pmid18953806">{{cite journal |vauthors=Bilimoria KY, Zanocco K, Sturgeon C |title=Impact of surgical treatment on outcomes for papillary thyroid cancer |journal=Adv Surg |volume=42 |issue= |pages=1–12 |date=2008 |pmid=18953806 |doi= |url=}}</ref><ref name="pmid22435914">{{cite journal |vauthors=Stack BC, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, Sosa JA, Tufano RP |title=American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer |journal=Thyroid |volume=22 |issue=5 |pages=501–8 |date=May 2012 |pmid=22435914 |doi=10.1089/thy.2011.0312 |url=}}</ref><ref name="pmid25590215">{{cite journal |vauthors=Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Torregrossa L, Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, Miccoli P |title=Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study |journal=J. Clin. Endocrinol. Metab. |volume=100 |issue=4 |pages=1316–24 |date=April 2015 |pmid=25590215 |doi=10.1210/jc.2014-3825 |url=}}</ref> | ||
* [[Surgical]] [[interventions]] of papillary thyroid cancer include total [[thyroidectomy]] and [[lobectomy]]. Each of these has its [[indications]]. | * [[Surgical]] [[interventions]] of papillary thyroid cancer include total [[thyroidectomy]] and [[lobectomy]]. Each of these has its [[Indications and usage|indications]]. | ||
==indications== | ==indications== | ||
* Total [[thyroidectomy]] is usually reserved for [[patients]] with either:<ref name="urlNCCN Clinical Practice Guidelines in Oncology">{{cite web |url=https://www.nccn.org/professionals/physician_gls/default.aspx#site |title=NCCN Clinical Practice Guidelines in Oncology |format= |work= |accessdate=}}</ref><ref name="pmid18953806">{{cite journal |vauthors=Bilimoria KY, Zanocco K, Sturgeon C |title=Impact of surgical treatment on outcomes for papillary thyroid cancer |journal=Adv Surg |volume=42 |issue= |pages=1–12 |date=2008 |pmid=18953806 |doi= |url=}}</ref><ref name="pmid22435914">{{cite journal |vauthors=Stack BC, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, Sosa JA, Tufano RP |title=American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer |journal=Thyroid |volume=22 |issue=5 |pages=501–8 |date=May 2012 |pmid=22435914 |doi=10.1089/thy.2011.0312 |url=}}</ref><ref name="pmid25590215">{{cite journal |vauthors=Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Torregrossa L, Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, Miccoli P |title=Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study |journal=J. Clin. Endocrinol. Metab. |volume=100 |issue=4 |pages=1316–24 |date=April 2015 |pmid=25590215 |doi=10.1210/jc.2014-3825 |url=}}</ref> | * Total [[thyroidectomy]] is usually reserved for [[patients]] with either:<ref name="urlNCCN Clinical Practice Guidelines in Oncology">{{cite web |url=https://www.nccn.org/professionals/physician_gls/default.aspx#site |title=NCCN Clinical Practice Guidelines in Oncology |format= |work= |accessdate=}}</ref><ref name="pmid18953806">{{cite journal |vauthors=Bilimoria KY, Zanocco K, Sturgeon C |title=Impact of surgical treatment on outcomes for papillary thyroid cancer |journal=Adv Surg |volume=42 |issue= |pages=1–12 |date=2008 |pmid=18953806 |doi= |url=}}</ref><ref name="pmid22435914">{{cite journal |vauthors=Stack BC, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, Sosa JA, Tufano RP |title=American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer |journal=Thyroid |volume=22 |issue=5 |pages=501–8 |date=May 2012 |pmid=22435914 |doi=10.1089/thy.2011.0312 |url=}}</ref><ref name="pmid25590215">{{cite journal |vauthors=Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Torregrossa L, Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, Miccoli P |title=Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study |journal=J. Clin. Endocrinol. Metab. |volume=100 |issue=4 |pages=1316–24 |date=April 2015 |pmid=25590215 |doi=10.1210/jc.2014-3825 |url=}}</ref> | ||
Line 16: | Line 16: | ||
** In case of [[bilateral]] nodularity | ** In case of [[bilateral]] nodularity | ||
** Prior [[radiation]] exposure | ** Prior [[radiation]] exposure | ||
* Total [[thyroidectomy]] or [[lobectomy]] is indicated if all of these criteria are present: | * Total [[thyroidectomy]] or [[lobectomy]] is [[Indications and usage|indicated]] if all of these criteria are present: | ||
** No prior [[radiation]] exposure | ** No prior [[radiation]] exposure | ||
** No distant [[metastasis]] | ** No distant [[metastasis]] | ||
Line 27: | Line 27: | ||
** No suspicious [[lymph nodes]] | ** No suspicious [[lymph nodes]] | ||
** Small [[tumors]] (< 1 cm) found incidentally on the final [[pathology]] sections | ** Small [[tumors]] (< 1 cm) found incidentally on the final [[pathology]] sections | ||
* [[Lobectomy]] plus isthmusectomy is recommended for [[patients]] who are not willing to take | * [[Lobectomy]] plus isthmusectomy is recommended for [[patients]] who are not willing to take [[thyroxine]] replacement therapy for the rest of their lives. | ||
* Total [[thyroidectomy]] should be performed after lobectomy plus isthmusectomy if either of these criteria is present: | * Total [[thyroidectomy]] should be performed after [[lobectomy]] plus [[isthmusectomy]] if either of these criteria is present: | ||
** Large [[tumor]] (> 4 cm) | ** Large [[tumor]] (> 4 cm) | ||
** Positive resection margins | ** Positive resection margins | ||
** Gross extra-thyroidal extension | ** Gross extra-thyroidal extension | ||
** Macroscopic multi-focal [[disease]] | **[[Macroscopic]] multi-focal [[disease]] | ||
** [[Vascular]] invasion | **[[Vascular]] invasion | ||
** Macroscopic nodal [[metastasis]] | **[[Macroscopic]] nodal [[metastasis]] | ||
==References== | ==References== |
Revision as of 15:29, 15 August 2019
Papillary thyroid cancer Microchapters |
Differentiating Papillary thyroid cancer from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Papillary thyroid cancer surgery On the Web |
American Roentgen Ray Society Images of Papillary thyroid cancer surgery |
Risk calculators and risk factors for Papillary thyroid cancer surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Surgery is the mainstay of treatment for papillary thyroid cancer. Surgical interventions of papillary thyroid cancer include total thyroidectomy and lobectomy. Each of these has its indications.
Surgery
- Surgery remains the mainstay of treatment for papillary thyroid cancer.[1][2][3][4]
- Surgical interventions of papillary thyroid cancer include total thyroidectomy and lobectomy. Each of these has its indications.
indications
- Total thyroidectomy is usually reserved for patients with either:[1][2][3][4]
- Known distant metastasis
- Extra-thyroidal extension
- Tumor> 4 cm in diameter
- Cervical lymph node metastasis
- Poorly differentiated tumor
- In case of bilateral nodularity
- Prior radiation exposure
- Total thyroidectomy or lobectomy is indicated if all of these criteria are present:
- No prior radiation exposure
- No distant metastasis
- No cervical lymph node metastasis
- No extra-thyroidal extension
- Tumor≤ 4 cm
- Lobectomy is considered curative if all of the following are present:
- Negative resection margins
- No contralateral lesion
- No suspicious lymph nodes
- Small tumors (< 1 cm) found incidentally on the final pathology sections
- Lobectomy plus isthmusectomy is recommended for patients who are not willing to take thyroxine replacement therapy for the rest of their lives.
- Total thyroidectomy should be performed after lobectomy plus isthmusectomy if either of these criteria is present:
- Large tumor (> 4 cm)
- Positive resection margins
- Gross extra-thyroidal extension
- Macroscopic multi-focal disease
- Vascular invasion
- Macroscopic nodal metastasis
References
- ↑ 1.0 1.1 "NCCN Clinical Practice Guidelines in Oncology".
- ↑ 2.0 2.1 Bilimoria KY, Zanocco K, Sturgeon C (2008). "Impact of surgical treatment on outcomes for papillary thyroid cancer". Adv Surg. 42: 1–12. PMID 18953806.
- ↑ 3.0 3.1 Stack BC, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, Sosa JA, Tufano RP (May 2012). "American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer". Thyroid. 22 (5): 501–8. doi:10.1089/thy.2011.0312. PMID 22435914.
- ↑ 4.0 4.1 Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P, Seccia V, Sensi E, Romei C, Piaggi P, Torregrossa L, Sellari-Franceschini S, Basolo F, Vitti P, Elisei R, Miccoli P (April 2015). "Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study". J. Clin. Endocrinol. Metab. 100 (4): 1316–24. doi:10.1210/jc.2014-3825. PMID 25590215.